Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)

UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)

UBS analyst Trung Huynh reiterated a Neutral rating and $633.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Bottom-line: we view today's interim readout as a small positive for the space, and highlights REGN's potentially underappreciated obesity pipeline. On the heels of... More

RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "BOTTOM LINE: In-line ph.II data show potential role of trevogrumab in obesity for better quality weight loss, though rapidly... More

BMO Capital Comments on Regeneron Pharma (REGN): 'COURAGE Data/Obesity License Move REGN Forward'

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $600.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst comments "Regeneron licenses GLP-1/GIP receptor agonist, HS-20094, for $80M in upfront fees and $1.9B in milestones. Ph 2 data for HS-20094 looks... More

RBC Capital Downgrades Regeneron Pharma (REGN) to Sector Perform

(Updated - May 30, 2025 12:38 PM EDT)

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Sector Perform with a price target of $662.00 (from $943.00).

The analyst commented, "We are downgrading REGN to Sector Perform following disappointing... More

Guggenheim Reiterates Buy Rating on Regeneron Pharma (REGN)

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $810.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "This morning REGN (and partner SAN.PAR) announced mixed results from the itepekimab (IL-33 mAb) program for COPD in former smokers. AERIFY-1 (n=1,127) met the primary endpoint (21-27% reduction in exacerbations) and AERIFY-2 (n=953) did not (2-12% reduction). The AERIFY-1 results were... More

Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)

Baird analyst Brian Skorney reiterated a Neutral rating and $587.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Incrementally negative on itepekimab results. REGN had caught a bounce over the last few weeks as investor anticipation of these Phase 3 results built... More

BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $800.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "A statistically significant benefit in only one of two AERIFY studies muddies the water for itepekimab in COPD. A statistically significant reduction... More

Wells Fargo Downgrades Regeneron Pharma (REGN) to Equal Weight

Wells Fargo analyst Mohit Bansal downgraded Regeneron Pharma (NASDAQ: REGN) from Overweight to Equal Weight with a price target of $580.00 (from $700.00).

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $605.39 yesterday.

Oppenheimer Reiterates Outperform Rating on Regeneron Pharma (REGN)

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $900.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Regeneron and partner Sanofi announced top-line results from the AERIFY-1 and 2 trials via press release. Recall that Itepekimab was Regenerons shot at consolidating COPD,... More

Regeneron (REGN) Reports Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use of itepekimab in adults who were former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit. A second Phase 3 trial, AERIFY-2, did not meet the same primary endpoint, although a benefit was seen earlier in the trial.

In the trials, patients were randomized to receive itepekimab every two weeks (AERIFY-1: n=375; AERIFY-2: n=326),... More

Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)

Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $958.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Looking ahead for the stock we expect the near-term focus to be on progress with HD Eylea, while over the medium term this will place increased focus on the company's mid to late stage pipeline to deliver. Trial efficacy and safety results: (1) Efficacy: Specifically, AERIFY-1 met the primary endpoint of significantly reducing moderate or severe acute exacerbations by... More

Regeneron shares slide on mixed trial data for smoker's lung drug

By Sriparna Roy

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. 

Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD). 

Investors had pinned their hopes on the drug,... More

Sanofi, Regeneron shares nosedive after mixed Itepekimab results

Investing.com -- Shares in Sanofi (EPA: SASY) (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.

Sanofis U.S.-listed shares... More

RBC Capital Previews Regeneron Pharma (REGN): 'Deep Dive Suggests Plenty Of Reasons For Optimism'

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $943.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented: "Deep Dive Suggests Plenty Of Reasons For Optimism Into Itepekimab Ph.III COPD Data; Our deep dive on preclinical and clinical... More